Adagene Inc ADR ADAG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.27
- Day Range
- $3.20–3.55
- 52-Week Range
- $1.30–4.85
- Bid/Ask
- $3.25 / $3.65
- Shares Outstanding
- 67.14M
- Market Cap
- $222.24M
- Volume/Avg
- 224,589 / 266,875
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.51
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 128
- Website
- https://www.adagene.com
Valuation
|
Metric
|
ADAG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.48 |
Price/Sales | 18.51 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADAG
|
|---|---|
Quick Ratio | 4.86 |
Current Ratio | 5.02 |
Interest Coverage | −80.89 |
Quick Ratio
ADAG
Profitability
|
Metric
|
ADAG
|
|---|---|
Return on Assets (Normalized) | −16.95% |
Return on Equity (Normalized) | −28.99% |
Return on Invested Capital (Normalized) | −29.47% |
Return on Assets
ADAG
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|w?p#B^Y | LOCK|@^d#t | $130B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%sV!GkY | LOCK|#ggMC | $82B | |||
| argenx SE ADR
ARGX
| LOCK|r@pMRl | LOCK|??? | $62B | |||
| Moderna Inc
MRNA
| LOCK|Qd<vdc> | LOCK|>% | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<^RQ@x | LOCK|qQ> | $40B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gFBm$tm | LOCK|XHgY | $33B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|tL>kc$gL | LOCK|y?>@ | $26B | |||
| Incyte Corp
INCY
| LOCK|MDq#d&X | LOCK|Z?F | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|B%<t$$l | LOCK|j^ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<j@hq$< | LOCK|%$n | $16B |
United States